全球甲狀腺疾病治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計甲狀腺疾病治療市場將從 2025 年的 28.5 億美元成長到 2034 年的 40.1 億美元，2026 年至 2034 年的複合年成長率為 3.87%。

由於全球甲狀腺甲狀腺機能低下症、甲狀腺功能亢進症和甲狀腺癌的盛行率不斷上升，全球甲狀腺疾病治療市場正經歷穩定成長。人們對早期診斷和定期篩檢項目的日益重視推動了市場擴張。碘缺乏症和自體免疫疾病（如橋本氏甲狀腺炎和葛瑞夫茲氏病）發病率的增加進一步刺激了治療需求。醫療服務可近性的提高和學名藥的普及也促進了市場成長。

成長要素包括老年人口不斷增加，而老年人罹患甲狀腺功能障礙的風險較高；以及診斷技術的進步。荷爾蒙補充療法和標靶癌症治療的創新正在改善治療效果。已開發國家不斷上漲的醫療成本和有利的報銷政策進一步刺激了市場需求。此外，微創手術在甲狀腺疾病治療中的日益普及也促進了市場的穩定發展。

展望未來，個人化醫療和生物製藥治療可望創造新的成長機會。對標靶治療的持續研究和藥物製劑的改進有望提高患者依從性和治療效果。新興經濟體由於醫療基礎設施的改善，預計將實現更高的成長率。隨著全球對內分泌健康意識的不斷提高，甲狀腺疾病治療市場有望繼續穩步擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球甲狀腺疾病治療市場：依適應症分類

• 市場分析、洞察與預測
• 甲狀腺機能低下症
• 甲狀腺功能亢進

第5章：全球甲狀腺疾病治療市場：依藥物分類

• 市場分析、洞察與預測
• 左甲狀腺素
• 三碘甲狀腺胺酸
• 丙硫氧嘧啶
• 咪唑類化合物
• 其他

第6章 全球甲狀腺疾病治療市場：依通路分類

• 市場分析、洞察與預測
• 批發分銷
• 零售店
• 網路藥房

第7章 全球甲狀腺疾病治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈注射
• 其他

第8章 全球甲狀腺疾病治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Viatris Inc
  • Novartis AG
  • Pfizer Inc
  • Takeda Pharmaceutical Company Limited
  • Elexis Inc
  • IBSA Institut Biochimique SA（IBSA Group）

The Thyroid Gland Disorder Treatment Market size is expected to reach USD 4.01 Billion in 2034 from USD 2.85 Billion (2025) growing at a CAGR of 3.87% during 2026-2034.

The Global Thyroid Gland Disorder Treatment Market is witnessing steady growth due to the rising prevalence of hypothyroidism, hyperthyroidism, and thyroid cancer worldwide. Increasing awareness about early diagnosis and routine screening programs is supporting market expansion. Growing incidences of iodine deficiency and autoimmune disorders such as Hashimoto's thyroiditis and Graves' disease further drive treatment demand. Improved access to healthcare services and availability of generic medications are also contributing to market growth.

Key drivers include the aging population, which is more prone to thyroid dysfunction, and advancements in diagnostic technologies. Pharmaceutical innovations in hormone replacement therapies and targeted cancer treatments enhance treatment outcomes. Rising healthcare expenditure and favorable reimbursement policies in developed nations further stimulate demand. Additionally, increasing adoption of minimally invasive surgical procedures for thyroid disorders supports the market's steady development.

Looking ahead, personalized medicine and biologic therapies are expected to create new growth opportunities. Continuous research in targeted therapies and improved drug formulations will enhance patient compliance and efficacy. Emerging economies are projected to witness higher growth due to improving healthcare infrastructure. As awareness about endocrine health increases globally, the thyroid gland disorder treatment market is likely to expand consistently.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Hypothyroidism
• Hyperthyroidism

By Drug

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based Compounds
• Others

By Distribution Channel

• Wholesale Distribution
• Retail Stores
• Online Pharmacy

By Route of Administration

• Oral
• Intravenous
• Others

COMPANIES PROFILED

• AbbVie Inc, Amgen Inc, GlaxoSmithKline plc, Merck KGaA, Viatris Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Institut Biochimique SA IBSA Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Hypothyroidism Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hyperthyroidism Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY DRUG 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug
• 5.2. Levothyroxine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liothyronine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Propylthiouracil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Imidazole-based Compounds Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Wholesale Distribution Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Indication
  • 8.2.2 By Drug
  • 8.2.3 By Distribution Channel
  • 8.2.4 By Route Of Administration
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Indication
  • 8.3.2 By Drug
  • 8.3.3 By Distribution Channel
  • 8.3.4 By Route Of Administration
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Indication
  • 8.4.2 By Drug
  • 8.4.3 By Distribution Channel
  • 8.4.4 By Route Of Administration
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Indication
  • 8.5.2 By Drug
  • 8.5.3 By Distribution Channel
  • 8.5.4 By Route Of Administration
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Indication
  • 8.6.2 By Drug
  • 8.6.3 By Distribution Channel
  • 8.6.4 By Route Of Administration
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL THYROID GLAND DISORDER TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Amgen Inc
  • 10.2.3 GlaxoSmithKline Plc
  • 10.2.4 Merck KGaA
  • 10.2.5 Viatris Inc
  • 10.2.6 Novartis AG
  • 10.2.7 Pfizer Inc
  • 10.2.8 Takeda Pharmaceutical Company Limited
  • 10.2.9 Elexis Inc
  • 10.2.10 IBSA Institut Biochimique SA (IBSA Group)